Clinical trial
Treatment of Retinal Vein Occlusion (RVO) With Open-Label Anecortave Acetate…
NCT00211354 · Manhattan Eye, Ear & Throat Hospital, Other · Withdrawn
Key facts
| NCT number | NCT00211354 |
|---|---|
| Title | Treatment of Retinal Vein Occlusion (RVO) With Open-Label Anecortave Acetate (15mg.) |
| Lead sponsor | Manhattan Eye, Ear & Throat Hospital, Other |
| Collaborators | Alcon Research Industry |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Retinal Vein Occlusion |
| Intervention type | Drug |
| Interventions | Anecortave Acetate |
| Enrollment | 0 |
| Start date | Mar 1, 2002 |
| Primary completion | Mar 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Sep 21, 2005 |
| Last update posted | Feb 4, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: